Among low- to intermediate-risk MCL patients (MIPI score between 0 and 5), our study revealed that SAMHD1-positive patients had worse PFS and OS compared with SAMHD1-negative patients. The gene discussed is SAMHD1; the disease is mantle cell lymphoma.